A silent epidemic

- There are more than 10 million people living with chronic hepatitis B or C across the Region of the Americas.
- In the Americas there are nearly 350 deaths each day from liver cancer and cirrhosis– complications of viral hepatitis.
- Without a comprehensive public policy response and funding to combat viral hepatitis, deaths will increase over the coming years.
- Hepatitis C has a cure! PAHO can support governments to scale-up national responses.

Contact us

Strategic Fund / Pan American Health Organization

525 Twenty-third Street, N.W.
Washington, D.C. 20037
202-974-3000

strategicfund@paho.org
www.paho.org/strategicfund

Hepatitis treatment saves lives

- More than 60% of liver cancer cases are due to late testing and treatment of viral hepatitis B and C.
- Recommended hepatitis B and C treatments are highly effective, and reduce the risk of liver cancer by more than 75%. New hepatitis C medicines can cure > 95% of people within in 3 months, while treatment for hepatitis B is simple, safe and shows no resistance. Medicines and diagnostics for both are available through PAHO Strategic Fund.
- Early testing for hepatitis prevents liver cancer and cirrhosis.
- Innovative pangenotipic treatment for Hepatitis C.
- Diagnostics and treatment prequalified by WHO.

The Pan American Health Organization is leading the fight against hepatitis. PAHO supports Ministries of Health to better understand the epidemics and align action towards eliminating hepatitis using the latest tools available.
PAHO Strategic Fund

What is it?
The Strategic Fund of the Pan American Health Organization is a regional mechanism for pooled procurement of essential medicines and strategic public health supplies for the countries of the Americas. The Fund pools demand from multiple countries and calls for international competitive bidding to procure quality-assured medicines and supplies at lower prices.

The purpose of the Strategic Fund is to improve access to quality, safe, and effective medicines and health supplies, while ensuring affordability, and promoting efficient and sustainable health systems.

Benefits of using the Strategic Fund

Quality, safety, and efficacy
Compliance with international standards on production and control.

Eligibility
WHO prequalification processes. Registration and commercialization in National Regulatory Authorities of Regional Reference.

Performance
Supplier performance evaluation.

Who can use it?
All health ministries and government institutions providing public health services in Members States of the Pan American Health Organization/World Health Organization (PAHO/WHO) can procure medicines and supplies through the Strategic Fund after signing an agreement with the Organization.

What products are available?
The Strategic Fund added high-cost medicines for hepatitis C to its Products List, offering these medicines at more affordable prices to countries of the Americas.

Products
- Daclastavir
- Dasabuvir
- Ledipasvir + Sofosbuvir
- Sofosbuvir
- Sofosbuvir + Velpastavir

Diagnostics PQ (with reference price):
- Expert - OraQuick - SD Bioline
- Inno-Lia - Bioelisa -Murex